• WedgeWPP just WON Sensodyne + Aquafresh + wellness globally in Oct 2025 — this is the strongest WPP-defend/expand pitch surface in this batch. Sensodyne TW activation falls under WPP Media TW scope by inheritance.
• WhyHaleon spun off from GSK July 2022 (LSE listing) — created fresh global agency reviews from the start.
• Who ·

1. W1WPP just WON Sensodyne + Aquafresh + wellness globally in Oct 2025 — this is the strongest WPP-defend/expand pitch surface in this batch. Sensodyne TW activation falls under WPP Media TW scope by inheritance.
2. W2Voltaren / Panadol go to Publicis globally — but TW-local OTC retail and pharmacy activation typically has more local agency latitude
3. W3Centrum (multivitamin) is wellness scope → WPP — strong TW retail/pharmacy fit
4. W4Cluster-led regional marketing means SEA decisions could route through SG — WPP Media APAC needs to align with TW local needs
5. W5Pharmacy shopper marketing (Watsons/Cosmed) is a tangible local-execution wedge vs global creative
6. W6Pivot to TW: Asian sensitive-teeth incidence + aging population (Voltaren/Centrum) creates local content opportunities

• Haleon spun off from GSK July 2022 (LSE listing) — created fresh global agency reviews from the start.
• Oct 2025 — Haleon completed global creative review consolidating from 3 holding companies (WPP, IPG, Publicis) to 2: WPP leads wellness + oral health (Sensodyne, Aquafresh); Publicis takes OTC (Voltaren, Panadol, Advil). IPG was dropped.
• WPP relationship is FRESH and rising — Sensodyne + Aquafresh + wellness brands (Centrum, Caltrate, Emergen-C) moved to WPP in Oct 2025. This is the strongest WPP-defend / WPP-expand surface in this batch.
• Haleon global media spend ~$1.2B in 2024 (Comvergence estimate) — significant.
• SEA + Taiwan is run as a cluster — regional ownership (Singapore/HK-based) rather than country marketing director model.
• Pharmacy/Watsons/Cosmed channel is critical in TW for retail OTC + wellness — shopper marketing is meaningful.

• Abhisek PandaRegional Marketing Director, Pain & Respiratory, Southeast Asia & Taiwan

  since 2025

  Covers SEA + Taiwan for Pain (Voltaren, Panadol) and Respiratory categories. Prior GSK roles in Sensodyne and Pain. Indicates regional cluster ownership rather than pure-TW country marketing lead.

  Source ↗
• Randy SilvaRegional Marketing Manager, Sensodyne, Southeast Asia & Taiwan

  since unknown

  Sensodyne regional ownership for SEA + Taiwan. Successful product launches and campaign initiatives across the SEA cluster.

  Source ↗

Consumer health spin-off (GSK Consumer Healthcare → LSE July 2022). Post-Oct 2025 review: WPP leads wellness + oral health globally (Sensodyne is the flagship), Publicis leads OTC pain + cold/flu (Voltaren, Panadol, Advil). Regional cluster ownership (SEA + TW). Heavy pharmacy/Watsons/Cosmed channel in TW. Sensodyne is the most marketed brand globally and likely in TW.

• Sensodyne 'Life's Too Short for Sensitive Teeth' refresh2025 · Publicis / TVision optimization (Publicis-led) · Integrated TVC + social

  High-speed cinematography + micro-audience targeting on Instagram/YouTube. Lowered avg consumer age, +4.5% market share gain in US/UK. TW likely adapts.

  Source ↗
• Voltaren pain relief category-building2024 · IPG (legacy) → Publicis (post-Oct 2025 review) · TVC + retail activation

  Topical pain relief positioning; OTC category education. Heavy on age 45+ joint-pain consumers in TW.

  Source ↗
• Centrum multivitamin daily wellness2024 · WPP (post-Oct 2025 wellness consolidation) · Digital + retail

  Daily multivitamin / wellness positioning; TW pharmacy + Watsons/Cosmed channel.

  Source ↗
• Panadol pain & fever family-care2024 · Publicis (OTC scope post-2025) · TVC + family-care campaigns

  Family pain/fever positioning; mother-targeted TW.

  Source ↗

Don't pitch against Publicis on Voltaren/Panadol/Advil — that's their freshly-won 2025 scope. Don't propose displacing the Sensodyne incumbent — WPP just won it, focus on growth/defend. Don't ignore the SEA cluster model — TW decisions route through Singapore-based regional ownership.

• Bayer Taiwan Consumer Health (Aspirin, Bepanthen, Berocca — direct OTC competitor)
• Kenvue Taiwan (Tylenol, Listerine, Neutrogena — direct pain/oral care/wellness competitor)
• Reckitt Taiwan (Strepsils, Nurofen, Mucinex)
• P&G Taiwan (Crest oral care)
• Local TW OTC: Yungshin, TTY Biopharm OTC arm

• ? Who is Haleon Taiwan country GM (separate from SEA regional marketing)?
• ? Which WPP agency (Mindshare? EssenceMediacom? Wavemaker?) holds the wellness + oral health media scope?
• ? What's the TW-specific spend split: Sensodyne vs Voltaren vs Centrum vs Panadol?
• ? Are there TW-local creative shops doing tactical work beneath the global WPP/Publicis splits?